BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.
In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.
Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus has been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the MHRA.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.
MHRA has granted conditional marketing authorisation for Autolus' treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.
Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
The Chancellor’s Autumn Budget placed life sciences at the forefront of the UK’s growth agenda, providing key support for R&D tax relief, medicines manufacturing, and sector-specific financing through the British Business Bank.
